NVZMF (Novonesis (Novozymes) B) LT-Debt-to-Total-Asset : 0.10 (As of Dec. 2024)

View and export this data going back to 2009. Start your Free Trial

What is Novonesis (Novozymes) B LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Novonesis (Novozymes) B's long-term debt to total assests ratio for the quarter that ended in Dec. 2024 was 0.10.

Novonesis (Novozymes) B's long-term debt to total assets ratio increased from Jun. 2023 (0.01) to Dec. 2024 (0.10). It may suggest that Novonesis (Novozymes) B is progressively becoming more dependent on debt to grow their business.

Novonesis (Novozymes) B LT-Debt-to-Total-Asset Historical Data

The historical data trend for Novonesis (Novozymes) B's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novonesis (Novozymes) B LT-Debt-to-Total-Asset Chart

Novonesis (Novozymes) B Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.02

0.14

0.16

0.10

Novonesis (Novozymes) B Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Jun24	Dec24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.01	0.01	0.16	0.07	0.10

Novonesis (Novozymes) B LT-Debt-to-Total-Asset Calculation

Novonesis (Novozymes) B's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (A: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2024 )	/	Total Assets (A: Dec. 2024 )
	=	1602.513	/	15911.623
	=	0.10

Novonesis (Novozymes) B's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (Q: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2024 )	/	Total Assets (Q: Dec. 2024 )
	=	1602.513	/	15911.623
	=	0.10

Novonesis (Novozymes) B (OTCPK:NVZMF) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Novonesis (Novozymes) B LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Novonesis (Novozymes) B's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Novonesis (Novozymes) B Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » Novonesis (Novozymes) B (OTCPK:NVZMF) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

NVZMY:USA NSISBc:UK 0Q4U:UK NSIS B:Denmark NZM2:Germany NZYM:Austria

Address

Krogshoejvej 36, Bagsvaerd, DNK, 2880

Website

https://www.novozymes.com

Novonesis was formed in 2024 through the merger of Novozymes and Chr. Hansen. Following the merger, the company became the world leader in industrial enzymes and microbial solutions, with a nearly 50% market share in both. The firm supplies a wide range of industry groups: household care, food and beverages, bioenergy, agriculture and feed, technical and pharmaceuticals. Its biological solutions create value for its customers by improving yield efficiency and performance, while saving energy and generating less waste. The company is headquartered in Denmark, employs around 10,000 people, and works across more than 30 research and development and application centers and 23 manufacturing sites.